Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT07469683 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT07469683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07469683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Recruiting
Start date
March 31, 2026
Completion date
October 31, 2029
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, malignant neoplasm of kidney, except renal pelvis, malignant neoplasms, neoplasms